Karyopharm officer nets PSUs, sells small stake

Karyopharm Therapeutics’ Chief Accounting Officer Kristin Abate reported the vesting of performance-based restricted stock units and a small share sale.

Rhea-AI Filing Summary

Karyopharm Therapeutics’ Chief Accounting Officer Kristin Abate reported the vesting of performance-based restricted stock units and a small share sale. On January 27, 2026, 92 shares of common stock were acquired at $0.0 upon PSUs vesting tied to revenue and total shareholder return milestones.

On January 28, 2026, Abate sold 50 shares of common stock at $7.03 per share to cover withholding tax from the PSU vesting under a pre-established automatic sale plan, described as non-discretionary. After these transactions, she directly owned 22,622 shares of Karyopharm common stock.

Insider Trade Summary

Net Seller: 50 shares

Net Sell 2 txns

Insider Abate Kristin

Role Chief Accounting Officer

Sold 50 shs ($351.50)

Type	Security	Shares	Price	Value
Sale	Common Stock	50	$7.03	$351.50
Grant/Award	Common Stock	92	$0.00	$0.00

Holdings After Transaction: Common Stock — 22,622 shares (Direct)

Footnotes (2)

1. F1. Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of the revenue and total shareholder return milestones as certified by the issuer's Compensation Committee on January 27, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on January 27, 2026.
2. F2. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did KPTI Chief Accounting Officer report?

Karyopharm’s Chief Accounting Officer Kristin Abate reported two transactions: 92 shares acquired from vested performance-based restricted stock units, then 50 shares sold at $7.03 to cover tax withholding. Following these moves, she directly held 22,622 shares of Karyopharm common stock.

How many KPTI shares did Kristin Abate sell and at what price?

Kristin Abate sold 50 shares of Karyopharm common stock at $7.03 per share. The sale was executed on January 28, 2026, through a broker-assisted transaction designed to satisfy withholding tax obligations arising from recently vested performance-based restricted stock units.

Why did KPTI’s Chief Accounting Officer sell shares in January 2026?

The 50-share sale was executed under a durable automatic sale instruction plan adopted May 27, 2021. It was specifically to cover withholding tax liability from the vesting of performance-based restricted stock units and is described as not being a discretionary trade by Kristin Abate.

What performance-based awards vested for KPTI’s Chief Accounting Officer?

92 shares of Karyopharm common stock were earned from performance-based restricted stock units granted in February 2023. They vested after revenue and total shareholder return milestones were certified as achieved by the Compensation Committee on January 27, 2026, with each PSU delivering one share upon vesting.

How many KPTI shares does Kristin Abate own after these transactions?

After the reported transactions, Kristin Abate directly owned 22,622 shares of Karyopharm common stock. This balance reflects the 92 shares received from vested performance-based restricted stock units and the subsequent sale of 50 shares to cover tax withholding obligations tied to that vesting.

Were Kristin Abate’s KPTI share sales discretionary trades?

The filing states the 50-share sale was made under a durable automatic sale instruction plan adopted in May 2021. It further clarifies that this broker-assisted sale, executed to cover tax withholding, does not represent a discretionary trade by Kristin Abate.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/29/2026 - 04:57 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Abate Kristin

(Last) (First) (Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON MA 02459

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/27/2026		A		92(1)	A	$0.0	22,672	D
Common Stock	01/28/2026		S(2)		50	D	$7.03	22,622	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of the revenue and total shareholder return milestones as certified by the issuer's Compensation Committee on January 27, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on January 27, 2026.

2. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.

	/s/ Nancy Smith as Attorney-in-Fact for Kristin Abate	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.